Oral simvastatin reduces the hypertensive response to air-jet stress

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 4, 2012, Pages 350-356

  Ufnal, Marcin ^a   Drapala, Adrian ^a   Sikora, Mariusz ^a   Szczepanska Sadowska, Ewa ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Angiotensin II; Blood pressure; Brain; Hypertension; Losartan; Statins; Stress; Vasopressin

Indexed keywords

ANGIOTENSIN II; LOSARTAN; SIMVACARD; SIMVASTATIN; TAP WATER; UNCLASSIFIED DRUG; VASOPRESSIN;

AIR JET STRESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; HEART RATE; HEMODYNAMICS; HYPERTENSION; MALE; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; STRESS;

ADMINISTRATION, ORAL; ANIMALS; COMPRESSED AIR; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; STRESS, PHYSIOLOGICAL;

EID: 84858962395     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2012.05675.x     Document Type: Article

References (39)

1. Esler M, Schwarz R. Management of hypertension complicated by psychiatric comorbidity. J. Clin. Hypertens. 2007; 9: 708-13.
2. Felder RB, Yu Y, Zhang ZH, Wei SG. Pharmacological treatment for heart failure: A view from the brain. Clin. Pharmacol. Ther. 2009; 86: 216-20.
3. Szczepanska-Sadowska E, Cudnoch-Jedrzejewska A, Ufnal M, Zera T. Brain and cardiovascular diseases. Common neurogenic background of cardiovascular, metabolic and inflammatory diseases. J. Physiol. Pharmacol. 2010; 61: 509-21.
4. Veerasingham SJ, Raizada MK. Brain renin-angiotensin system dysfunction in hypertension. Recent advances and perspectives. Br. J. Pharmacol. 2003; 139: 191-202.
5. Ufnal M, Sikora M. The role of brain gaseous transmitters in the regulation of the circulatory system. Curr. Pharm. Biotechnol. 2011; 12: 1322-33.
6. Szczepanska-Sadowska E. Neuropeptides in neurogenic disorders of the cardiovascular control. J. Physiol. Pharmacol. 2006; 57(Suppl. 11): 31-53.
7. Philippu A. Regulation of blood pressure by central neurotransmitters and neuropeptides. Rev. Physiol. Biochem. Pharmacol. 1988; 111: 1-115.
8. Ferguson AV, Washburn DL. Angiotensin II. A peptidergic neurotransmitter in central autonomic pathways. Prog. Neurobiol. 1998; 54: 169-92.
9. Brugts JJ, Yetgin T, Hoeks SE et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
10. Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: A review of the evidence. Clin. Endocrinol. 2009; 70: 815-28.
11. Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: A new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol. Rep. 2007; 59: 483-99.
12. Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002; 40: 142-7.
13. Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am. J. Cardiol. 1995; 75: 582-6.
14. Ledingham JM, Laverty R. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model. Clin. Exp. Pharmacol. Physiol. 2005; 32: 76-85.
15. Sposito AC, Mansur AP, Coelho OR, Nicolau JC, Ramires JA. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am. J. Cardiol. 1999; 83: 1497-9.
16. He YP, Zhao LY, Zheng QS et al. Involvement of ERK and AKT signaling in the growth effect of arginine vasopressin on adult rat cardiac fibroblast and the modulation by simvastatin. Mol. Cell. Biochem. 2008; 317: 33-41.
17. Ishikawa S, Kawasumi M, Saito T. Simvastatin inhibits the cellular signaling and proliferative action of arginine vasopressin in cultured rat glomerular mesangial cells. Endocrinology 1995; 136: 1954-61.
18. Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res. 1994; 11: 305-11.
19. Ufnal M, Sikora M, Zera T, Szczepanska-Sadowska E. Simvastatin reduces pressor response to centrally administered angiotensin II. Am. J. Hypertens. 2010; 23: 956-9.
20. Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Dobruch J et al. Differential sensitisation to central cardiovascular effects of angiotensin II in rats with a myocardial infarct: Relevance to stress and interaction with vasopressin. Stress 2008; 11: 290-301.
21. Milutinovic S, Murphy D, Japundzic-Zigon N. The role of central vasopressin receptors in the modulation of autonomic cardiovascular controls: A spectral analysis study. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006; 291: R1579-91.
22. Saiki Y, Watanabe T, Tan N, Matsuzaki M, Nakamura S. Role of central ANG II receptors in stress-induced cardiovascular and hyperthermic responses in rats. Am. J. Physiol. 1997; 272: R26-33.
23. Manning M, Stoev S, Bankowski K et al. Synthesis and some pharmacological properties of potent and selective antagonists of the vasopressor (V1-receptor) response to arginine-vasopressin. J. Med. Chem. 1992; 35: 382-8.
24. 1 and V1 receptors in cardiovascular adaptation to hemorrhage in SD and renin TGR rats. Am. J. Physiol. 1999; 276: H1918-26.
25. Zera T, Ufnal M. Enhanced pressor response to centrally administered vasopressin in WKY rats on high sodium diet. Acta Neurobiol. Exp. 2005; 65: 145-50.
26. Huang BS, Leenen FH. Sympathoexcitatory and pressor responses to increased brain sodium and ouabain are mediated via brain ANG II. Am. J. Physiol. 1996; 270: H275-80.
27. Ufnal M, Dudek M, Zera T, Szczepanska-Sadowska E. Centrally administered interleukin-1 beta sensitizes to the central pressor action of angiotensin II. Brain Res. 2006; 1100: 64-72.
28. Ufnal M, Sikora M, Szczepanska-Sadowska E. Interleukin-1 receptor antagonist reduces the magnitude of the pressor response to acute stress. Neurosci. Lett. 2008; 448: 47-51.
29. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 1998; 81: 582-7.
30. 1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications. Psychoneuroendocrinology 2011; 36: 1-18.
31. 1 receptors in the RVLM mediate pressor responses to emotional stress in rabbits. Hypertension 2003; 41: 1168-73.
32. Gao L, Wang W, Li YL et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: Roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005; 112: 1763-70.
33. Ruperez M, Rodrigues-Diez R, Blanco-Colio LM et al. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: Role of RhoA/ROCK and MAPK pathways. Hypertension 2007; 50: 377-83.
34. Toney GM, Porter JP. Effects of blockade of AT1 and AT2 receptors in brain on the central angiotensin II pressor response in conscious spontaneously hypertensive rats. Neuropharmacology 1993; 32: 581-9.
35. Mateos L, Ismail MA, Gil-Bea FJ et al. Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer's disease. J. Alzheimers Dis. 2011; 24: 669-79.
36. Cibickova L, Hyspler R, Micuda S et al. The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid beta and cholesterol synthesis in rat brain. Steroids 2009; 74: 13-19.
37. Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J. Am. Coll. Cardiol. 2003; 42: 1091-7.
38. Dibona GF, Jones SY, Sawin LL. Effect of endogenous angiotensin II on renal nerve activity and its cardiac baroreflex regulation. J. Am. Soc. Nephrol. 1998; 9: 1983-9.
39. Dimsdale JE. Psychological stress and cardiovascular disease. J. Am. Coll. Cardiol. 2008; 51: 1237-46.